A pilot randomized trial to prevent sexual dysfunction in postmenopausal breast cancer survivors starting adjuvant aromatase inhibitor therapy
- PMID: 28229275
- DOI: 10.1007/s11764-017-0606-3
A pilot randomized trial to prevent sexual dysfunction in postmenopausal breast cancer survivors starting adjuvant aromatase inhibitor therapy
Abstract
Purpose: A randomized pilot trial evaluated the hypothesis that early intervention lessens sexual dysfunction in the first year on aromatase inhibitors. A secondary aim was comparing the efficacy of two vaginal moisturizers.
Methods: Fifty-seven postmenopausal women with early stage breast cancer starting aromatase inhibitors were randomized to three treatment groups. All received a handout on managing sexual and other side effects. The Usual Care group received no additional therapy. The Active Treatment groups received a 6-month supply of a vaginal moisturizer (hyaluronic acid-based in Active Group-H and prebiotic in Active Group-P) and a vaginal lubricant and dilator, plus access to an educational website and phone coaching. Questionnaires completed at baseline, 6, and 12 months included the Female Sexual Function Index (FSFI), Menopausal Sexual Interest Questionnaire (MSIQ), Female Sexual Distress Scale-Revised (FSDS-R), and a menopausal symptom scale.
Results: Forty-nine women (86%) provided follow-up data. Mean age was 59 and 77% were non-Hispanic Caucasian. Sexual function was impaired at baseline, but remained stable over 12 months for all groups. The combined active treatment group had less dyspareunia (P = 0.07) and sexual distress (P = 0.02) at 6 months than the Usual Care group. At 6 months, the Active-H group improved significantly more than the Active-P group on FSFI total score (P = 0.04).
Conclusions: Sexual counseling helped women maintain stable sexual function on aromatase inhibitors. Active intervention resulted in better outcomes at 6 months.
Implications for cancer survivors: This promising pilot trial suggests a need for more research on preventive counseling to maintain sexual function during aromatase inhibitor treatment.
Keywords: Aromatase inhibitors; Breast cancer; Dyspareunia; Genitourinary atrophy; Prevention; Sexual dysfunction.
Similar articles
-
Effect of Fractional Carbon Dioxide vs Sham Laser on Sexual Function in Survivors of Breast Cancer Receiving Aromatase Inhibitors for Genitourinary Syndrome of Menopause: The LIGHT Randomized Clinical Trial.JAMA Netw Open. 2023 Feb 1;6(2):e2255697. doi: 10.1001/jamanetworkopen.2022.55697. JAMA Netw Open. 2023. PMID: 36763359 Free PMC article. Clinical Trial.
-
Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal Symptoms Associated With Aromatase Inhibitors.J Clin Endocrinol Metab. 2018 Nov 1;103(11):4146-4154. doi: 10.1210/jc.2018-01345. J Clin Endocrinol Metab. 2018. PMID: 30239842 Clinical Trial.
-
Aromatase Inhibitors Are Associated With Low Sexual Desire Causing Distress and Fecal Incontinence in Women: An Observational Study.J Sex Med. 2017 Dec;14(12):1566-1574. doi: 10.1016/j.jsxm.2017.09.018. Epub 2017 Oct 21. J Sex Med. 2017. PMID: 29066307
-
The impact of aromatase inhibitors on sexual functioning: current knowledge and future research directions.Breast. 2008 Oct;17(5):436-40. doi: 10.1016/j.breast.2008.04.001. Epub 2008 May 14. Breast. 2008. PMID: 18479922 Review.
-
Sexual dysfunction and aromatase inhibitor use in survivors of breast cancer.Clin Breast Cancer. 2009 Nov;9(4):219-24. doi: 10.3816/CBC.2009.n.037. Clin Breast Cancer. 2009. PMID: 19933076 Review.
Cited by
-
Sexual Health after a Breast Cancer Diagnosis: Addressing a Forgotten Aspect of Survivorship.J Clin Med. 2022 Nov 14;11(22):6723. doi: 10.3390/jcm11226723. J Clin Med. 2022. PMID: 36431200 Free PMC article. Review.
-
Attitudes and Behavior of Patients with Gynecologic Malignancy Towards Sexual Issues: a Single-institutional Survey.J Cancer Educ. 2021 Jun;36(3):497-503. doi: 10.1007/s13187-019-01653-9. J Cancer Educ. 2021. PMID: 31808051 Free PMC article.
-
Hyaluronic Acid: A Valid Therapeutic Option for Early Management of Genitourinary Syndrome of Menopause in Cancer Survivors?Healthcare (Basel). 2022 Aug 13;10(8):1528. doi: 10.3390/healthcare10081528. Healthcare (Basel). 2022. PMID: 36011183 Free PMC article. Review.
-
Ovarian Suppression: Early Menopause and Late Effects.Curr Treat Options Oncol. 2024 Apr;25(4):523-542. doi: 10.1007/s11864-024-01190-8. Epub 2024 Mar 13. Curr Treat Options Oncol. 2024. PMID: 38478329 Free PMC article. Review.
-
Digital Health Interventions for Adult Patients With Cancer Evaluated in Randomized Controlled Trials: Scoping Review.J Med Internet Res. 2023 Jan 6;25:e38333. doi: 10.2196/38333. J Med Internet Res. 2023. PMID: 36607712 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical